Realtime | Geld | Brief | Zeit |
---|---|---|---|
14,000 | 14,300 | 01.04. |
Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting | Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab... ► Artikel lesen |
Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides... ► Artikel lesen |
Oruka Therapeutics, Inc.: Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody | Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy... ► Artikel lesen |
Palvella Therapeutics Inc.: Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update | Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical... ► Artikel lesen |
Palvella Therapeutics Inc.: Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger ... | Expansion reflects Palvella's commitment to serving all patients affected by microcystic lymphatic malformations (microcystic LMs) Company remains on track to report top line results from SELVA, a... ► Artikel lesen |
XFRA IVH,PR9,U04,6L00,2KZ0,W2B,MI70,1IY0,B1Q,PI6: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 20.11.2024 | The following instruments on XETRA do have their first trading 20.11.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.11.2024
Aktien
1 PLRNBWT00031 Rainbow Tours S.A.
2... ► Artikel lesen |
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates | NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases... ► Artikel lesen |
Pre-market Movers: BTC Digital, XBP Europe, Neurogene, 1847 Holdings, Taysha Gene Therapies | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.00 A.M. ET).In the Green BTC Digital Ltd. (BTCT) is up over 78% at $4.50.
XBP... ► Artikel lesen |